Trial · NCT02842086
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of HIV-1 Infection Per 100 Person Years (PY) | Descovy (DVY) | 0.160 | 95% Confidence Interval 0.064 to 0.330 | HIV-1 infections per 100 PY | |
| Incidence of HIV-1 Infection Per 100 Person Years (PY) | Truvada (TVD) | 0.342 | 95% Confidence Interval 0.191 to 0.564 | HIV-1 infections per 100 PY | |
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase | Descovy (DVY) | 0.218 | Standard Deviation 2.3668 | Percent Change | |
| Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48 in the Blinded Phase | Truvada (TVD) | -0.968 | Standard Deviation 2.4343 | Percent Change | |
| Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase | Descovy (DVY) | 0.512 | Standard Deviation 2.9854 | Percent Change | |
| Percent Change From Baseline in Spine BMD at Week 48 in the Blinded Phase | Truvada (TVD) | -1.061 | Standard Deviation 2.9382 | Percent Change | |
| Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase | Descovy (DVY) | -10.6 | Inter-Quartile Range -42.0 to 25.9 | Percent Change | |
| Percent Change From Baseline in Urine Beta-2-Microglobulin to Creatinine Ratio at Week 48 in the Blinded Phase | Truvada (TVD) | 15.4 | Inter-Quartile Range -22.9 to 97.2 | Percent Change | |
| Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase | Descovy (DVY) | 0.1 | Inter-Quartile Range -24.9 to 35.3 | Percent Change | |
| Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48 in the Blinded Phase | Truvada (TVD) | 20.0 | Inter-Quartile Range -13.0 to 68.2 | Percent Change | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Descovy (DVY) | ≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 2318 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Truvada (TVD) | ≤ 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 2295 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Descovy (DVY) | ≤ 200 mg/g at Baseline; > 200 mg/g at Week 48 | 16 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Truvada (TVD) | ≤ 200 mg/g at Baseline; > 200 mg/g at Week 48 | 35 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Descovy (DVY) | > 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 12 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Truvada (TVD) | > 200 mg/g at Baseline; ≤ 200 mg/g at Week 48 | 8 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Descovy (DVY) | > 200 mg/g at Baseline; > 200 mg/g at Week 48 | 9 | Participants | |
| Number of Participants by Urine Protein (UP) and Urine Protein to Creatinine Ratio (UPCR) Categories at Week 48 in the Blinded Phase | Truvada (TVD) | > 200 mg/g at Baseline; > 200 mg/g at Week 48 | 10 | Participants | |
| Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase | Descovy (DVY) | -0.01 | Standard Deviation 0.107 | mg/dL | |
| Change From Baseline in Serum Creatinine at Week 48 in the Blinded Phase | Truvada (TVD) | 0.01 | Standard Deviation 0.111 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02842086/results